Patents Represented by Attorney, Agent or Law Firm Thomas D. Webster
  • Patent number: 5776695
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: July 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5773214
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus flavus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus flavus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: June 30, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert B. Peery, Paul L. Skatrud
  • Patent number: 5770415
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: June 23, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5712108
    Abstract: The invention provides isolated nucleic acid compounds encoding the murE stem peptide biosynthetic gene of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the murE enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: May 29, 1996
    Date of Patent: January 27, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert Brown Peery, Paul Luther Skatrud
  • Patent number: 5710018
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 20, 1998
    Assignee: Eli Lilly and Company
    Inventors: Anne H. Dantzig, Jo Ann Hoskins, Paul L. Skatrud
  • Patent number: 5705352
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus fumigatus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus fumigatus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: January 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert B. Peery, Paul L. Skatrud
  • Patent number: 5698444
    Abstract: This invention describes a novel human serotonin receptor, designated 5-HT.sub.2B. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: December 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: Melvyn Baez, Jonathan D. Kursar
  • Patent number: 5691161
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: November 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5681694
    Abstract: The invention provides isolated nucleic acid compounds encoding the murD stem peptide biosynthetic gene of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurD enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: October 28, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Robert Brown Peery, Paul Luther Skatrud, Chyun-Yeh Earnest Wu
  • Patent number: 5658755
    Abstract: Heterologous extra-cellular expression of recombinant proteins in soluble functional form is desirable because of the ease associated with purification of the secreted proteins and avoidance of the need for cell extraction and protein refolding procedures. The present invention provides DNA sequences of the naturally-occurring phthalyl amidase gene isolated from Xanthobacter agilis that control transcription, translation, and extra-cellular secretion of proteins in Streptomyces lividans. These DNA sequences can be used in a method for extra-cellular expression of a wide variety of proteins in soluble functional form.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: August 19, 1997
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 5620855
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Eli Lilly and Company
    Inventors: Anne H. Dantzig, Jo A. Hoskins, Paul L. Skatrud